{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-062321","form_type":"8-K","ticker":null,"cik":"0001017491","company_name":"SEELOS THERAPEUTICS, INC.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.898079+00:00","generated_at":"2026-06-01T18:28:12.280705+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Seelos Therapeutics announces 1-for-8 reverse stock split to regain Nasdaq compliance","bullets":["Reverse stock split at 1-for-8 ratio, effective May 16, 2024, at 12:01 a.m. ET.","Authorized shares reduced from 400M to 50M; par value unchanged at $0.001.","No fractional shares; fractions rounded up to nearest whole share.","Purpose: meet Nasdaq $1.00 minimum bid price requirement; symbol remains SEEL.","Outstanding warrants and stock options proportionately adjusted; equity plan shares reduced."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-062321","json":"https://secwatch.observer/filing/0001104659-24-062321.json","markdown":"https://secwatch.observer/filing/0001104659-24-062321.md","text":"https://secwatch.observer/filing/0001104659-24-062321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1017491/000110465924062321/0001104659-24-062321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1017491/000110465924062321/tm2414386d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T18:28:12.280705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e368b99847cba1807865c61db77c232bce49823","claim":"SEELOS THERAPEUTICS, INC.: Filed Certificate of Change to effect a 1-for-8 reverse stock split and decrease authorized shares from 400,000,000 to 50,000,000 (effective 2024-05-16).","evidence_excerpt":"On May 15, 2024, Seelos Therapeutics, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to (i) effect a 1-for-8 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), and (ii) decrease the number of total authorized shares of Common Stock from 400,000,000 shares to 50,000,000 shares.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1017491/000110465924062321/0001104659-24-062321-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-05-16"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}